Well-Differentiated Papillary Mesothelioma

Well-differentiated papillary mesothelioma (WDPM) is a rare tumor that grows from the lining (mesothelium) of the abdomen, chest, or, less often, the pericardium or tunica vaginalis. Unlike malignant mesothelioma, it usually behaves in a slow, non-aggressive way and is now classified by pathologists as a tumor of uncertain or borderline malignant potential rather than a frank cancer. It often appears as small surface nodules and is most commonly found in women, sometimes as an incidental finding during surgery for another reason.

Origin

The entity was first described in the peritoneum in 1979 by Daya and McCaughey, who identified a distinct papillary lesion that did not behave like conventional malignant mesothelioma. The World Health Organization formally recognized it as a separate diagnostic category, and in the 2021 WHO classification it was renamed "well-differentiated papillary mesothelial tumor" to reflect its generally indolent course.

Significance in Asbestos Context

For patients, the distinction between WDPM and malignant mesothelioma is critical because the prognosis, treatment, and legal posture can be very different. WDPM is often managed with surgery or observation rather than aggressive chemotherapy, and many patients live for years or decades. The link to asbestos exposure is weaker and more debated than for malignant mesothelioma (some series report asbestos histories in a minority of patients, while others find no clear connection), so defendants in asbestos litigation often dispute causation when the diagnosis is WDPM. If your pathology report uses the words "well-differentiated papillary," it is important that an experienced mesothelioma pathologist confirms the diagnosis, because WDPM can be confused with early or in-situ malignant mesothelioma, and the legal and medical consequences of that distinction are substantial.

Example Sentence

After her hysterectomy, the surgeon sent peritoneal nodules to pathology, and the report came back as well-differentiated papillary mesothelioma rather than malignant mesothelioma, a finding her oncologist wanted a second opinion to confirm.

Related Terms

Peritoneal Mesothelioma, Malignant Mesothelioma, Mesothelium, BAP1, Pathology Review, Immunohistochemistry

Notes

• Request a second-opinion pathology review at a mesothelioma specialty center (such as MD Anderson, Memorial Sloan Kettering, Brigham and Women's, or an academic center with a dedicated mesothelioma program) before accepting WDPM as the final diagnosis. Distinguishing it from invasive mesothelioma can change everything about treatment and prognosis.
• Ask whether BAP1 immunohistochemistry and other molecular markers were performed; loss of BAP1 is more typical of malignant mesothelioma and can help separate the two.
• Preserve all imaging, operative reports, and pathology slides (not just the report). Slides may need to be sent out for review and are also evidence in any legal claim.
• Document any occupational, household, or environmental asbestos exposure carefully even if your diagnosis is WDPM; the causal link is contested and your legal team will need a detailed exposure history to evaluate whether a claim is viable.
• Discuss long-term surveillance with your oncologist, because WDPM can recur or, in rare cases, progress, and follow-up imaging schedules vary by institution.